Anlon Healthcare IPO: Final Day Sees Moderate Subscription, What's Next for Investors?

The Anlon Healthcare IPO, which concluded its subscription period on December 28, 2023, saw a total subscription of 4.07 times. This eagerly watched SME IPO aimed to raise Rs 15.30 crore through the issuance of 15.30 lakh equity shares at a fixed price of Rs 100 per share.

Investors had a narrow window from December 26 to December 28, 2023, to participate in this offering.

The IPO, which will list on the NSE SME platform, had set a lot size of 1200 shares. On the final day of bidding, the retail investor segment showed significant interest, subscribing 5.64 times its allotted portion. Non-institutional investors (NIIs) also demonstrated moderate interest, with their segment being subscribed 2.50 times.

However, Qualified Institutional Buyers (QIBs) remained largely on the sidelines, with a subscription of only 0.16 times.

The Grey Market Premium (GMP) for Anlon Healthcare IPO was reported to be around Rs 10. While GMP can offer a preliminary indication of market sentiment and potential listing gains, it's a dynamic and unofficial figure, not to be solely relied upon for investment decisions.

Anlon Healthcare Limited specializes in trading, marketing, and distributing pharmaceutical products.

Their portfolio includes a wide range of offerings from antibiotics and antifungals to vitamins and pain relievers. The company has a diverse customer base, including hospitals, clinics, and government institutions, primarily serving the Gujarat and Chhattisgarh markets. Proceeds from the IPO are earmarked to meet working capital requirements and for general corporate purposes, crucial for funding the company's growth and operational expansion.

For those who applied, the allotment for the Anlon Healthcare IPO was tentatively scheduled for December 29, 2023, with the listing on the NSE SME platform expected on January 2, 2024.

This marks a critical phase for investors to monitor the listing performance and decide on their next steps. While the overall subscription was decent, the subdued QIB interest often prompts a more cautious approach from market observers.